Company news

Dare Bioscience, Inc. news in 2025

Dare Bioscience, Inc.'s news releases, calls and decks from 2025, newest first.

View company

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

December 10, 2025

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

December 1, 2025

Dare Bioscience Receives $3.6 Million in Additional Grant Funding

November 25, 2025

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

November 24, 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health

November 12, 2025

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

November 11, 2025

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

November 6, 2025

Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

November 3, 2025

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

October 6, 2025

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

September 24, 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

August 7, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

July 29, 2025

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

July 21, 2025

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

July 14, 2025

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

July 11, 2025

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

June 12, 2025

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream

June 4, 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

May 6, 2025

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

April 23, 2025

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

April 7, 2025

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

March 31, 2025

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

March 24, 2025

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

February 20, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

February 5, 2025

Calls in 2025

Decks in 2025